title: Maternal colonization with group B Streptococcus and prelabor rupture of membranes at term: the role of induction of labor. TermPROM Study Group.
abstract: OBJECTIVE
  Our purpose was to determine the effect of induction of labor on neonatal infection if mothers are group B streptococci positive and have prelabor rupture of membranes at term.
  
  
  METHODS
  In the TermPROM study 5041 women were randomized to induction with intravenous oxytocin, induction with vaginal prostaglandin E2 gel, or expectant management with induction, if needed. Of these, 4834 women had vaginal or introital swabs for group B streptococci taken at entry. We used logistic regression to test for effects of treatment within group B streptococci subgroups.
  
  
  RESULTS
  Group B streptococci were predictive of neonatal infection for the induction with vaginal prostaglandin E2 gel and expectant groups but not for the induction with oxytocin group. For women positive for group B streptococci the rates of neonatal infection were 2.5% for the induction with oxytocin group and > 8% for all other groups.
  
  
  CONCLUSIONS
  Induction of labor with intravenous oxytocin may be preferable for group B streptococci-positive women with prelabor rupture of membranes at term.
authors.affiliation: Department of Obstetrics and Gynaecology, University of Toronto, Ontario, Canada.
authors.forename: M E
authors.initials: ME
authors.lastname: Hannah
authors.forename: A
authors.initials: A
authors.lastname: Ohlsson
authors.forename: E E
authors.initials: EE
authors.lastname: Wang
authors.forename: A
authors.initials: A
authors.lastname: Matlow
authors.forename: G A
authors.initials: GA
authors.lastname: Foster
authors.forename: A R
authors.initials: AR
authors.lastname: Willan
authors.forename: E D
authors.initials: ED
authors.lastname: Hodnett
authors.forename: J A
authors.initials: JA
authors.lastname: Weston
authors.forename: D
authors.initials: D
authors.lastname: Farine
authors.forename: P G
authors.initials: PG
authors.lastname: Seaward
mesh_terms: D000282:Administration, Intravaginal; D015232:Dinoprostone / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000382:microbiology*; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D007751:Labor, Induced; D016015:Logistic Models; D010121:Oxytocin / Q000008:administration & dosage / Q000627:therapeutic use; D011247:Pregnancy; D013290:Streptococcal Infections / Q000517:prevention & control / Q000635:transmission*; D013292:Streptococcus agalactiae / Q000302:isolation & purification*; D014621:Vagina / Q000382:microbiology
chemical_list: D010121:Oxytocin; D015232:Dinoprostone